Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer
Not Applicable
- Conditions
- Oesophageal Cancer
- Registration Number
- NCT00220077
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Brief Summary
Knowledge of the impact of gene expression profiling could allow optimisation of chemotherapy regimens for individual patients. It could ensure that patients do not receive a particular form of chemotherapy if it is unlikely to benefit them, and in these circumstances an alternative form of chemotherapy that may prove beneficial could be selected. This information will therefore allow chemotherapy to be tailored to the individual tumour. It may help identify those patients with a poorer prognosis who could be selected for further therapy post surgery or a different treatment strategy at the outset.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- Any patient with histologically proven operable ,locally advanced and metastatic oesophageal or gastric carcinoma.
Exclusion Criteria
- Second malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.
- Secondary Outcome Measures
Name Time Method Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.
Trial Locations
- Locations (1)
Royal Marsden Hospital
🇬🇧Sutton, Surrey, United Kingdom